Diversified Consumer Services
Company Overview of Thomas Jefferson University
Thomas Jefferson University is a medical and health sciences university offering education to future physicians, nurses, and scientists. It offers programs in fields such as biotechnology, cytotechnology, diagnostic imaging, cardiovascular technology, medical technology, nursing, and occupational therapy. The colleges of the university include Jefferson Medical College, Jefferson College of Graduate Studies, and Jefferson College of Health Professions. Thomas Jefferson University was formerly known as Jefferson Medical College. The university was established in 1824 and is based in Philadelphia, Pennsylvania. Thomas Jefferson University has endowment assets worth $651.3 millions.
130 South 9th Street
Philadelphia, PA 19107-5233
Founded in 1824
Key Executives for Thomas Jefferson University
Chair of the Department of Microbiology and Immunology
Professor and Chair of Surgery
Vice President and University Counsel
Senior Vice President of Academic Affairs
Founding Chair of Department of Neuroscience - Jefferson Medical College
Compensation as of Fiscal Year 2015.
Thomas Jefferson University Key Developments
Exosome Sciences, Inc. Enters into Research Collaboration with Thomas Jefferson University
Apr 2 15
Aethlon Medical, Inc. disclosed that its Exosome Sciences, Inc. has entered into a research collaboration with Thomas Jefferson University. The goal of the collaboration is to advance a "liquid biopsy" that could improve the diagnoses and monitoring of head and neck cancer. In this regard, researchers will seek to determine whether exosome-based molecular signatures correlate with and predict patient responses to therapy.
ANGLE plc Signs Research Agreement with the Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 30 14
ANGLE plc has signed a research agreement with the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia to investigate the clinical use of the Parsortix system in metastatic breast cancer patients. The research collaboration will be led by Dr. Massimo Cristofanilli, an internationally renowned breast cancer researcher and clinician, and Director of the Jefferson Breast Care Center at the Sidney Kimmel Cancer Center (SKCC) and Thomas Jefferson University and Hospitals. Dr. Cristofanilli's research aims to improve personalised medicine for breast cancer patients, focusing on molecular targeted agents, biomarkers and gene therapies. Dr. Cristofanilli has been an acknowledged leader in the CTC field since 2004, when his study on CTCs was published in The New England Journal of Medicine. His study found CTCs to be a predictor of progression-free survival and overall survival in metastatic breast cancer patients, and was one of the first major studies on CTCs. Dr. Cristofanilli and his team are particularly interested in ANGLE's Parsortix system for CTCs because it is antibody independent and offers easy harvesting of CTCs for molecular analysis, which may help guide treatment plans.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries